All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023

Staff shortages cause slowdowns in booming cell and gene therapy market

New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.

By Karissa Waddick • April 3, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Leaders wave a magic wand at pharma’s thorniest issues

The major challenges pharma leaders would solve with a quick flick of an imaginary wand.

By PharmaVoice staff • March 31, 2023

Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

By Michael Gibney • March 30, 2023

Pharma’s salesforce is suffering — what does version 2.0 look like?

Ahead of turbulent market conditions, an industry markets leader encourages companies to rethink their sales strategy.

By Kelly Bilodeau • March 28, 2023

SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi

The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market.

By Michael Gibney • March 28, 2023

How one of the world’s sharpest inventors keeps the ideas coming. Hint: It’s not at work

Steve Quake, head of science for the Chan Zuckerberg Initiative, who’s had several “once-in-a-lifetime” ideas, provides advice on how to find inspiration.

By Alexandra Pecci • March 27, 2023

Cutting the cord — why streaming is a new frontier for pharma advertising

As streaming services proliferate, and more TV watchers buy in, there’s a new world of possibilities for DTC pharma marketing.

By Karissa Waddick • March 27, 2023

What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials

How life science execs would transform clinical trials with a little hocus pocus.

By PharmaVoice staff • March 24, 2023

This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once

The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.

By Michael Gibney • March 23, 2023

Everyone says they’re patient-centric, but have they really walked the walk?

Life science leaders provide practical tips on how to create a sustainable patient-focused culture.

By Karissa Waddick • March 23, 2023

Viral roots: A look at how modern outbreaks began

As experts wrestle with COVID-19’s lab leak versus animal market debate, here’s what experts say are the suspected origins for some of the worst viral outbreaks in the last century.

By Meagan Parrish • March 22, 2023

SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape

Although many pharma and biotech companies had deposits at the failed bank, most have reported little to no exposure.

By Michael Gibney • March 21, 2023

Changing the channel from TV to the pharmacy boosts DTC ROI

While a TV spot still has its allure, the level of engagement provided through the pharmacy channel is more than a little compelling.

By Heather Campbell, VP Marketing, Adheris Health • March 20, 2023

In the fallout from Aduhelm, Biogen’s leadership shakeup continues

The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

By Karissa Waddick • March 16, 2023

Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.

By Michael Gibney • March 16, 2023

The PharmaVoice 100 — Who makes the cut

What we’re looking for in each new class of honorees.

By Meagan Parrish • March 15, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

By Michael Gibney • March 14, 2023

Biden doubles down on drug pricing in 2024 budget — but boosts R&D

The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.

By Karissa Waddick • March 13, 2023

Across therapy areas, GoodRx’s POS rebates improve access and affordability for cash-paying patients

Across therapy areas, GoodRx Assist is a proven point-of-sale rebate program for cash-paying patients.

March 13, 2023

IQVIA’s OG of data analytics on the latest clinical trial trends

IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

By Taren Grom • March 10, 2023

Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

By Michael Gibney • March 9, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023